Table 2.
Linear mixed model analysis to examine the effect of domperidone on serum symmetric dimethylarginine (sSDMA), serum creatinine (sCr), and sSDMA-to-sCr ratio (sSDMA/sCr) in group T (treatment) compared with group C (control) at different time points (i.e., T0–T3)
| Parameters* | Time points | P§ | |||||
|---|---|---|---|---|---|---|---|
| T0 (a) |
T1 (b) |
T2 (c) |
T3 (d) |
(b) vs (a) |
(c) vs (a) |
(d) vs (a) |
|
| sSDMA (μg/dl) | |||||||
| Group T | 17.15 ± 2.77 | 15.25 ± 3.65 | 13.58 ± 3.37 | 15.67 ± 2.27 | 0.01 | < 0.001 | 0.03 |
| Group C | 15.10 ± 3.60 | 10.60 ± 3.89 | 12.20 ± 4.66 | 14.10 ± 4.84 | < 0.001 | 0.02 | 0.59 |
| P† | 0.05 | 0.003 | 0.44 | 0.37 | |||
| Mixed‡ |
Treatment 0.04 |
Time < 0.0001 |
Interaction 0.07 |
||||
| sCr (mg/dl) | |||||||
| Group T | 1.15 ± 0.17 | 0.99 ± 0.16 | 0.96 ± 0.16 | 1.14 ± 0.20 | 0.02 | 0.01 | 0.90 |
| Group C | 1.11 ± 0.36 | 1.00 ± 0.64 | 1.08 ± 0.75 | 1.27 ± 0.94 | 0.27 | 0.90 | 0.03 |
| P† | 0.42 | 0.75 | 0.71 | 0.68 | |||
| Mixed‡ |
Treatment 0.93 |
Time 0.0002 |
Interaction 0.24 |
||||
| sSDMA/sCr | |||||||
| Group T | 15.78 ± 3.93 | 15.39 ± 2.95 | 14.29 ± 3.42 | 13.96 ± 2.54 | 0.69 | 0.13 | 0.06 |
| Group C | 13.88 ± 2.01 | 11.80 ± 4.02 | 12.58 ± 4.31 | 12.64 ± 3.22 | 0.13 | 0.42 | 0.45 |
| P† | 0.15 | 0.02 | 0.35 | 0.51 | |||
| Mixed‡ |
Treatment 0.08 |
Time 0.26 |
Interaction 0.42 |
||||
*As mean and standard deviation (M ± SD)
†Treatment effect for each time
‡Mixed effects
§Contrasts of marginal linear predictions